On 11/8/24, Travere Therapeutics Inc (NASDAQ: TVTX) stock enjoyed a major increase of 12.4%, closing at $19.85. Moreover, this advance was accompanied by unusually high trading volume at 184% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 13.4% during the last week.
Current PriceTarget Research Rating
TVTX’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Travere Therapeutics has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Travere Therapeutics has a very low Appreciation Score of 6 but a very high Power Rating of 97, leading to the Neutral Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment